Shares of Rapid7 slid 7% to $11.11 on Monday, extending a punishing decline that has erased more than 70% of shareholder value over the past year. The latest leg down crystallizes a deepening credibility problem: the company keeps beating quarterly earnings, yet its forward guidance keeps getting worse — and analysts are running out of patience.

  • The Numbers Tell a Story of Stalling Growth. In February, Rapid7 reported Q4 2025 revenue of $217 million but guided full-year 2026 revenue to just $835–$843 million — well below the Street's $869.7 million consensus . Annual recurring revenue (ARR) — the subscription income cybersecurity firms live and die by — decelerated to 0% growth year-over-year . That means the company isn't adding net new customers fast enough to offset losses elsewhere, a devastating signal in a sector where peers are still growing.

  • Analysts Are Cutting Targets in Waves. JPMorgan, Barclays, Raymond James, Piper Sandler, Canaccord, Morgan Stanley, William Blair, Truist, Mizuho, and RBC Capital have all lowered their Rapid7 price targets or ratings in recent months . Barclays dropped its target to just $6.50, maintaining an Underweight rating and citing negative annual recurring revenue growth . The consensus among 17 analysts is now a lukewarm "Hold" . When nearly every major bank downgrades at once, institutional buyers step aside — and the stock loses its safety net.

  • The Business Is Splitting in Two. Barclays estimates roughly 45% of Rapid7's business is declining in the mid-teens percentage range. That's the legacy vulnerability-scanning segment — software that checks networks for known weaknesses. Management says its newer detection-and-response services continue to grow , but the old business is shrinking faster than the new one is expanding. The company has projected a 2–3% revenue decline for the year and stopped providing recurring-revenue guidance altogether , removing a key metric investors rely on.

  • A Leadership Shake-Up Adds Uncertainty. DA Davidson raised its target to $6.50 — still far below today's price — after the CEO role shifted to Wael Mohamed, with founder Corey Thomas moving to Executive Chairman . Mohamed was nominated by activist investor Jana Partners , signaling boardroom pressure to accelerate change. Whether new leadership can reverse the revenue slide before cash flow deteriorates is the question that separates a turnaround bet from a value trap.

At $11.11, the stock trades above most bearish targets but well below optimistic fair-value models. Until guidance stabilizes, Rapid7 remains a show-me story with no clear catalyst in sight.